Celebrate International Clinical Trials' Day, ECRIN Urges
ECRIN is encouraging all clinical researchers to get involved in International Clinical Trials' Day.
The European Clinical Research Infrastructure Network (ECRIN) is encouraging all clinical researchers to get involved in International Clinical Trials' Day (ICTD), which takes place today (May 20).
ICTD is designed to coincide with the day that the Scottish physician James Lind started his famous trial in 1747. He was a pioneer of naval hygiene, and by conducting the first ever clinical trial, he developed the theory that citrus fruits cured scurvy. The objective is to make May 20 a focal point for international communication events, meetings, debates, and celebrations of clinical research.
This will be followed on May 21 by a project meeting being organized by ECRIN, ECRAN (European Communication on Research Awareness Needs), ICTD and CRP (Clinical Research Program) in Luxembourg. This meeting aims to promote a transnational communication on multinational clinical trials with the objective of facilitating better clinical research relevant to the needs of patients and highlight the important role of patients in clinical research.
For further details, go to http://www.ecranproject.eu/en/content/communicate-clinical-research-two-days-two-great-event.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
